Inactive Instrument

Highlights Taxus Cardium Pharmaceuticals Group Inc OTC Bulletin Board

Equities

CRXM

US1419163043

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2022	Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
2021	Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	04/21/04	CI
Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product	26/21/26	CI
Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc	14/18/14	CI
Gene Biotherapeutics Mulls Acquisitions	08/18/08	CI
Taxus Cardium Pharmaceuticals Group Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Application	13/17/13	CI
Taxus Cardium Mulls Acquisitions	01/17/01	CI
Taxus Cardium Mulls Acquisitions	27/16/27	CI
Taxus Cardium Pharmaceuticals Group Inc. Enters into Binding Term Sheet with Dr. Reddy’S Laboratories Ltd	10/15/10	CI
TaxuCardium Pharmaceuticals Group Inc. Reports Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014	20/14/20	CI
TaxuCardium Pharmaceuticals Group Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014	12/14/12	CI
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx(R) Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention	24/14/24	CI
Cardium Therapeutics to Announce Interim Results of Generx Angiogenic Gene Therapy Phase 3 Clinical Study at the 2014 Bio International Convention	12/14/12	CI
TaxuCardium Pharmaceuticals Group Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2014	15/14/15	CI
TaxuCardium Pharmaceuticals Group Inc. Announces Selection of Excellagen(R) For Use With Stem Cells in European Union-Funded Human Clinical Study	12/14/12	CI
TaxuCardium Pharmaceuticals Group Inc. Announces Consolidated Earnings Results for the Year Ended December 31, 2013	15/14/15	CI
Cardium Therapeutics Reports on Advancement of Generx and Excellagen Biologic Products	31/13/31	CI
Cardium Therapeutics, Inc. Reports Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2013	19/13/19	CI
Cardium Therapeutics Inc. Reports Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2013	14/13/14	CI
Cardium Mulls Acquisitions	14/13/14	CI
Cardium Announces Excellagen Distribution Agreement with Kasiak for Germany and Switzerland	07/13/07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Taxus Cardium Pharmaceuticals Group Inc OTC Bulletin Board

Equities

CRXM

US1419163043

Highlights

Filters